The ETF world is becoming increasingly niche oriented lately and another niche ETF - the Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) - recently joined the fray. Biotech has been a popular place to create a new product lately as ETFs targeting companies involved in genomics, drugs in late stage clinical trials and medical breakthroughs have all hit the market in the past 12 months.
According to the fund's fact sheet, the Cancer Immunotherapy ETF "is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in this approach." It charges an expense ratio of 0.79% and equal weights the portfolio among 30 holdings.
Click the button below to read the rest of this original article on Seeking Alpha.
Got a question? A comment? A fund you want to see profiled? Let us know!